Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis.
The endocannabinoid pathway plays an important role in the regulation of appetite and body weight, hepatic lipid metabolism, and fibrosis. Blockade of the endocannabinoid receptor CB1 with SR141716 promotes weight loss, reduces hepatocyte fatty acid synthesis, and is antifibrotic. D-4F, an apolipoprotein A-1 mimetic with antioxidant properties, is currently in clinical trials for the treatment of atherosclerosis. C57BL/6J mice were fed a high-fat diet for 7 months, followed by a 2.5-month treatment with either SR141716 or D-4F. SR141716 markedly improved body weight, liver weight, serum transaminases, insulin resistance, hyperglycemia, hypercholesterolemia, hyperleptinemia, and oxidative stress, accompanied by the significant prevention of fibrosis progression. D-4F improved hypercholesterolemia and hyperleptinemia without improvement in body weight, steatohepatitis, insulin resistance, or oxidative stress, and yet, there was significant prevention of fibrosis. D-4F prevented culture-induced activation of stellate cells in vitro. In summary, C57BL/6J mice given a high-fat diet developed features of metabolic syndrome with nonalcoholic steatohepatitis and fibrosis. Both SR141716 and D-4F prevented progression of fibrosis after onset of steatohepatitis, ie, a situation comparable to a common clinical scenario, with D-4F seeming to have a more general antifibrotic effect. Either compound therefore has the potential to be of clinical benefit.
DeLeve
Laurie D
LD
Division of Gastrointestinal and Liver Diseases and the Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. deleve@usc.edu
Wang
Xiangdong
X
Kanel
Gary C
GC
Atkinson
Roscoe D
RD
McCuskey
Robert S
RS
D000199:Actins / Q000378:metabolism; D000818:Animals; D016632:Apolipoprotein A-I / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002478:Cells, Cultured; D004032:Diet; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000150:complications*; D022781:Hepatocytes / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D007249:Inflammation; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008103:Liver Cirrhosis / Q000150:complications* / Q000517:prevention & control*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D051379:Mice; D008810:Mice, Inbred C57BL; D009929:Organ Size / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D000077285:Rimonabant
D000199:Actins; D016632:Apolipoprotein A-I; C465468:D-4F peptide; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant
J Electron Microsc Tech. 1990 Mar;14(3):237-46
2338588
Hepatology. 2004 Aug;40(2):386-93
15368443
J Lipid Res. 2007 Sep;48(9):1915-23
17570869
Gastroenterology. 2005 Mar;128(3):742-55
15765409
J Biol Chem. 2002 Nov 29;277(48):45874-9
12244109
Circulation. 2002 Jan 22;105(3):290-2
11804981
Anal Biochem. 1993 Jan;208(1):10-5
8434778
Gastroenterology. 2002 May;122(5):1399-410
11984526
J Biol Chem. 2002 Mar 22;277(12):9853-64
11782477
J Gastroenterol Hepatol. 2001 Jun;16(6):599-606
11422610
Mol Endocrinol. 2006 Dec;20(12):3376-88
16931573
Anal Biochem. 1969 Mar;27(3):502-22
4388022
Arterioscler Thromb Vasc Biol. 1999 May;19(5):1223-30
10323773
Diabetologia. 1985 Jul;28(7):412-9
3899825
J Clin Invest. 2005 May;115(5):1298-305
15864349
J Gastroenterol Hepatol. 1995;10 Suppl 1:S50-3
8589343
Anat Rec (Hoboken). 2008 Jun;291(6):684-92
18484615
Hepatology. 2002 Jul;36(1):12-21
12085344
Circulation. 2004 Jun 29;109(25):3215-20
15197147
Hepatology. 2007 Jul;46(1):122-9
17526015
J Cell Biochem. 2003 May 15;89(2):311-20
12704794
Hepatology. 2001 Oct;34(4 Pt 1):729-37
11584369
Hepatology. 1998 Mar;27(3):720-6
9500700
Nat Med. 2006 Jun;12(6):671-6
16715087
Clin Chem. 1987 Feb;33(2 Pt 1):214-20
3802504
Mol Aspects Med. 2000 Jun;21(3):49-98
10978499
Hepatology. 1986 Sep-Oct;6(5):814-22
3758935